BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36107212)

  • 1. Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
    Font A; Domenech M; Buisan O; Lopez H; González A; Etxaniz O; Matas M; Elias X; Gomez M; Figols M; Horneros J; Pardo JC; Notario L; Ruiz de Porras V; Perez I; Areal J; Esteve A
    World J Urol; 2022 Nov; 40(11):2627-2634. PubMed ID: 36107212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nomogram Predicting Bladder Cancer-specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium.
    Mir MC; Marchioni M; Zargar H; Zargar-Shoshtari K; Fairey AS; Mertens LS; Dinney CP; Krabbe LM; Cookson MS; Jacobsen NE; Griffin J; Montgomery JS; Vasdev N; Yu EY; Xylinas E; McGrath JS; Kassouf W; Dall'Era MA; Sridhar SS; Aning J; Shariat SF; Wright JL; Thorpe AC; Morgan TM; Holzbeierlein JM; Bivalacqua TJ; North S; Barocas DA; Lotan Y; Grivas P; Stephenson AJ; Shah JB; van Rhijn BW; Spiess PE; Daneshmand D; Black PC
    Eur Urol Focus; 2021 Nov; 7(6):1347-1354. PubMed ID: 32771446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
    Bandini M; Briganti A; Plimack ER; Niegisch G; Yu EY; Bamias A; Agarwal N; Sridhar SS; Sternberg CN; Vaishampayan U; Théodore C; Rosenberg JE; Bellmunt J; Galsky MD; Montorsi F; Necchi A
    Eur Urol Oncol; 2019 May; 2(3):248-256. PubMed ID: 31200838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
    Ravi P; Pond GR; Diamantopoulos LN; Su C; Alva A; Jain RK; Skelton WP; Gupta S; Tward JD; Olson KM; Singh P; Grunewald CM; Niegisch G; Lee JL; Gallina A; Bandini M; Necchi A; Mossanen M; McGregor BA; Curran C; Grivas P; Sonpavde GP
    BJU Int; 2021 Nov; 128(5):607-614. PubMed ID: 33909949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of Disease after Bacillus Calmette-Guérin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy.
    Hensley PJ; Bree KK; Campbell MT; Alhalabi O; Kokorovic A; Miest T; Nogueras-Gonzalez GM; Gao J; Siefker-Radtke AO; Guo CC; Navai N; Dinney CP; Kamat AM
    J Urol; 2021 Nov; 206(5):1258-1267. PubMed ID: 34184926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma.
    Pokuri VK; Syed JR; Yang Z; Field EP; Cyriac S; Pili R; Levine EG; Azabdaftari G; Trump DL; Guru K; George S
    Clin Genitourin Cancer; 2016 Feb; 14(1):e59-65. PubMed ID: 26508364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of short-term outcomes of neoadjuvant chemotherapy followed by radical cystectomy in muscle-invasive bladder cancer: a single Egyptian institution experience.
    Abdelrahman I; Aboulkassem H; Elazab A; Abdallah AY; Ismail Y; Taher M
    J Egypt Natl Canc Inst; 2023 May; 35(1):13. PubMed ID: 37145329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood transfusions during neoadjuvant chemotherapy for muscle-invasive urinary bladder cancer may have a negative impact on overall survival.
    Rosenblatt R; Lorentzi G; Bahar M; Asad D; Forsman R; Johansson M; Shareef M; Alamdari F; Bergh A; Winqvist O; Sherif A
    Scand J Urol; 2020 Feb; 54(1):46-51. PubMed ID: 31960752
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathological Downstaging and Survival Outcomes Associated with Neoadjuvant Chemotherapy for Variant Histology Muscle Invasive Bladder Cancer.
    Chakiryan NH; Jiang DD; Gillis KA; Green E; Hajiran A; Hugar L; Zemp L; Zhang J; Jain R; Chahoud J; Poch M; Manley BJ; Li R; Sexton W; Gilbert SM
    J Urol; 2021 Oct; 206(4):924-932. PubMed ID: 34032503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
    Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
    Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel node detection in muscle-invasive urothelial bladder cancer is feasible after neoadjuvant chemotherapy in all pT stages, a prospective multicenter report.
    Rosenblatt R; Johansson M; Alamdari F; Sidiki A; Holmström B; Hansson J; Vasko J; Marits P; Gabrielsson S; Riklund K; Winqvist O; Sherif A
    World J Urol; 2017 Jun; 35(6):921-927. PubMed ID: 27738804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contemporary Rates of Gynecologic Organ Involvement in Females with Muscle Invasive Bladder Cancer: A Retrospective Review of Women Undergoing Radical Cystectomy following Neoadjuvant Chemotherapy.
    Bree KK; Hensley PJ; Westerman ME; Kokorovic A; Nogueras-Gonzalez GM; Dinney CP; Kamat AM; Navai N
    J Urol; 2021 Sep; 206(3):577-585. PubMed ID: 33872050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occult lymph node metastases in patients without residual muscle-invasive bladder cancer at radical cystectomy with or without neoadjuvant chemotherapy: a nationwide study of 5417 patients.
    van Hoogstraten LMC; van Gennep EJ; Kiemeney LALM; Witjes JA; Voskuilen CS; Deelen M; Mertens LS; Meijer RP; Boormans JL; Robbrecht DGJ; Beerepoot LV; Verhoeven RHA; Ripping TM; ; van Rhijn BWG; Aben KKH; Hermans TJN
    World J Urol; 2022 Jan; 40(1):111-118. PubMed ID: 34585294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer.
    Martini A; Jia R; Ferket BS; Waingankar N; Plimack ER; Crabb SJ; Harshman LC; Yu EY; Powles T; Rosenberg JE; Pal SK; Vaishampayan UN; Necchi A; Wiklund NP; Mehrazin R; Mazumdar M; Sfakianos JP; Galsky MD
    Cancer; 2019 Sep; 125(18):3155-3163. PubMed ID: 31150110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
    Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
    Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
    [No Abstract]   [Full Text] [Related]  

  • 16. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathological and Survival Outcomes Associated with Variant Histology Bladder Cancers Managed by Cystectomy with or without Neoadjuvant Chemotherapy.
    Hajiran A; Azizi M; Aydin AM; Zemp L; Peyton CC; Dhillon J; Nealon S; Reich RR; Cao B; Li R; Manley BJ; Sexton WJ; Gilbert SM
    J Urol; 2021 Jan; 205(1):100-108. PubMed ID: 32783489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes Following Clinical Complete Response to Neoadjuvant Chemotherapy for Muscle-invasive Urothelial Carcinoma of the Bladder in Patients Refusing Radical Cystectomy.
    Robins D; Matulay J; Lipsky M; Meyer A; Ghandour R; DeCastro G; Anderson C; Drake C; Benson M; McKiernan JM
    Urology; 2018 Jan; 111():116-121. PubMed ID: 29032239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle-invasive bladder cancer treated with cisplatin-based neoadjuvant chemotherapy and radical cystectomy: a single-centre experience.
    Boeri L; Soligo M; Frank I; Boorjian SA; Thompson RH; Tollefson M; Quevedo FJ; Cheville JC; Karnes RJ
    BJU Int; 2019 Jun; 123(6):1011-1019. PubMed ID: 30623554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.